+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Central Nervous System Drugs Market Research Reports

Peripheral Nerve Injuries - Pipeline Insight, 2025 - Product Thumbnail Image

Peripheral Nerve Injuries - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 50 Pages
  • Global
From
LRRK2 Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

LRRK2 Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
MELAS Sundrome - Pipeline Insight, 2025 - Product Thumbnail Image

MELAS Sundrome - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
GABA A Receptor Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

GABA A Receptor Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Dopamine D2 Receptor Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Dopamine D2 Receptor Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Dopamine D1 Receptor Antagonists - Pipeline Insight, 2025 - Product Thumbnail Image

Dopamine D1 Receptor Antagonists - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Autistic Disorder- Pipeline Insight, 2025 - Product Thumbnail Image

Autistic Disorder- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Lewy Body Disease- Pipeline Insight, 2025 - Product Thumbnail Image

Lewy Body Disease- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Trk (TrkB) Receptor Antagonists - Pipeline Insight, 2025 - Product Thumbnail Image

Trk (TrkB) Receptor Antagonists - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Sensorineural Hearing Loss (SHL) - Pipeline Insight, 2025 - Product Thumbnail Image

Sensorineural Hearing Loss (SHL) - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 80 Pages
  • Global
From
Dementia Associated With Alzheimer's Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Dementia Associated With Alzheimer's Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 240 Pages
  • Global
From
Glucagon-Like Peptide (GLP) Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

Glucagon-Like Peptide (GLP) Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 180 Pages
  • Global
From
5-HT1 Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

5-HT1 Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Tardive Dyskinesia - Pipeline Insight, 2025 - Product Thumbnail Image

Tardive Dyskinesia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Relapsing Multiple Sclerosis (RMS) - Pipeline Insight, 2025 - Product Thumbnail Image

Relapsing Multiple Sclerosis (RMS) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Hepatic Encephalopathy - Pipeline Insight, 2025 - Product Thumbnail Image

Hepatic Encephalopathy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Dystonia - Pipeline Insight, 2025 - Product Thumbnail Image

Dystonia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Seizures - Pipeline Insight, 2025 - Product Thumbnail Image

Seizures - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Insight, 2025 - Product Thumbnail Image

Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Loading Indicator

The Central Nervous System Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs that target the central nervous system. These drugs are used to treat a variety of conditions, including neurological disorders, mental health issues, and pain management. The market is composed of a variety of companies, ranging from large multinationals to small start-ups. The Central Nervous System Drugs market is highly competitive, with companies competing to develop the most effective and safe treatments. Companies in the market are constantly researching and developing new drugs, as well as improving existing treatments. Many of these companies are also involved in clinical trials to test the safety and efficacy of their products. Some of the major companies in the Central Nervous System Drugs market include Pfizer, GlaxoSmithKline, Merck, Novartis, and Johnson & Johnson. These companies are involved in the development and production of a wide range of CNS drugs, including antidepressants, antipsychotics, and anticonvulsants. Show Less Read more